Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16177
Title: Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial
Austin Authors: Tebbutt, Niall C ;Price, Timothy J;Ferraro, Danielle A;Wong, Nicole;Veillard, Anne-Sophie;Hall, Merryn;Sjoquist, Katrin M;Pavlakis, Nick;Strickland, Andrew;Varma, Suresh C;Cooray, Prasad;Young, Rosemary;Underhill, Craig;Shannon, Jennifer A;Ganju, Vinod;Gebski, Val J
Affiliation: Austin Health, Heidelberg, Victoria, Australia
The Queen Elizabeth Hospital, Woodville South, South Australia, Australia
NMHRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia
Royal North Shore Hospital, St Leonards, NSW, Australia
Monash Medical Centre, Clayton, Victoria, Australia
Townsville Hospital, Douglas, Queensland, Australia
Box Hill Hospital, Box Hill, Victoria, Australia
Royal Hobart Hospital, Hobart, Tasmania, Australia
Border Medical Oncology, Albury, NSW, Australia
Nepean Cancer Care Centre, Kingswood, NSW, Australia
Frankston Hospital, Frankston, Victoria, Australia
Issue Date: Mar-2016
metadata.dc.date: 2016-02-11
Publication information: British Journal of Cancer 2016; 114(5):505-509
Abstract: Background: This randomised phase II study evaluated the efficacy and safety of panitumumab added to docetaxel-based chemotherapy in advanced oesophagogastric cancer. Methods: Patients with metastatic or locally recurrent cancer of the oesophagus, oesophagogastric junction or stomach received docetaxel and a fluoropyrimidine with or without panitumumab for 8 cycles or until progression. The primary end point was response rate (RECIST1.1). We planned to enrol 100 patients, with 50% expected response rate for combination therapy. Results: A total of 77 patients were enrolled. A safety alert from the REAL3 trial prompted a review of data that found no evidence of adverse outcomes associated with panitumumab but questionable efficacy, and new enrolment was ceased. Enrolled patients were treated according to protocol. Response rates were 49% (95% CI 34–64%) in the chemotherapy arm and 58% (95% CI 42–72%) in the combination arm. Common grade 3 and 4 toxicities included infection, anorexia, vomiting, diarrhoea and fatigue. At 23.7 months of median follow-up, median progression-free survival was 6.9 months vs 6.0 months and median overall survival was 11.7 months vs 10.0 months in the chemotherapy arm and the combination arm, respectively. Conclusions: Adding panitumumab to docetaxel-based chemotherapy for advanced oesophagogastric cancer did not improve efficacy and increased toxicities.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16177
DOI: 10.1038/bjc.2015.440
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/26867157
Type: Journal Article
Subjects: Oesophago-gastric cancer
Chemotherapy
Randomised study
Panitumumab
Docetaxel
Type of Clinical Study or Trial: Randomized Controlled Clinical Trial/Controlled Clinical Trial
Appears in Collections:Journal articles

Show full item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.